Search results - 7 results
Isotypic neutralizing antibodies against mouse GCP-2/CXCL6 inhibit melanoma growth and metastasis
302, Issue 1, Number 62, p.54- 62 (2011) Keywords:)Melanoma chemokine Granulocyte chemotactic protein-2 (GCP-2 Abstract: The chemokine granulocyte chemotactic protein (GCP)-2/ CXCL6 promotes tumor growth ...
p53 expression and apoptosis in melanomas of dogs and cats.
Biopsy Cat Diseases Cats Disease Progression Dog Diseases Dogs In Situ Nick-End Labeling Melanins Melanoma Survival Rate Tumor Suppressor Protein p53 Abstract: Twenty-seven melanocytic tumours from 20 dogs ...
DNA ploidy and nuclear morphometric variables for the evaluation of melanocytic tumors in dogs and cats.
Biopsy Cat Diseases Cats Densitometry DNA, Neoplasm Dog Diseases Dogs Melanoma Ploidies Abstract: OBJECTIVE: To determine the prognostic importance of the DNA content and nuclear morphometric variables in ...
Proliferation, DNA ploidy, p53 overexpression and nuclear DNA fragmentation in six equine melanocytic tumours.
immunohistochemistry In Situ Nick-End Labeling Ki-67 Antigen Male Melanins Melanoma Ploidies Proliferating Cell Nuclear Antigen Rosaniline Dyes Skin Neoplasms Abstract: Melanocytic tumours are a well-known clinical and ...
PCNA and Ki67 proliferation markers as criteria for prediction of clinical behaviour of melanocytic tumours in cats and dogs.
Cell Division Disease Progression Dog Diseases Dogs Female Ki-67 Antigen Male Melanoma Neoplasm Proteins Proliferating Cell Nuclear Antigen Skin Neoplasms Abstract: Melanocytic tumours in domestic ...
Malignant melanoma of the nictitating membrane in a cat (Felis vulgaris).
Exophthalmos Eyelid Neoplasms Lung Neoplasms Male Melanoma Neoplasm Invasiveness Nictitating Membrane Orbital Neoplasms Abstract: A case of malignant melanoma of the nictitating membrane in a 10-year-old cat is ...
Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting.
important component in cancer care with the most application now in melanoma and lung cancer patients. Some drawbacks that converge with this new evolution are the rather low response rates to these drugs and ...